50 results on '"Chu, Cindy S"'
Search Results
2. Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis
- Author
-
Adhikari, Bipin, Anstey, Nicholas M, Assefa, Ashenafi, Boyd, Sarah C, Chau, Nguyen Hoang, Day, Nicholas PJ, Degaga, Tamiru Shibiru, Dondorp, Arjen M, Erhart, Annette, Ferreira, Marcelo Urbano, Ghimire, Prakash, Green, Justin A, Koh, Gavin CKW, Mekuria, Asrat Hailu, Mueller, Ivo, Naadim, Mohammad Nader, Nelwan, Erni J, Nosten, Francois, Price, David J, Sattabongkot, Jetsumon, Stepniewska, Kasia, von Seidlein, Lorenz, William, Timothy, Woodrow, Charles J, Woyessa, Adugna, Commons, Robert J, Rajasekhar, Megha, Edler, Peta, Abreha, Tesfay, Awab, Ghulam R, Baird, J Kevin, Barber, Bridget E, Chu, Cindy S, Cui, Liwang, Daher, André, Gonzalez-Ceron, Lilia, Grigg, Matthew J, Hwang, Jimee, Karunajeewa, Harin, Lacerda, Marcus V G, Ladeia-Andrade, Simone, Lidia, Kartini, Llanos-Cuentas, Alejandro, Longley, Rhea J, Pereira, Dhelio B, Pasaribu, Ayodhia P, Pukrittayakamee, Sasithon, Rijal, Komal R, Sutanto, Inge, Taylor, Walter R J, Thanh, Pham V, Thriemer, Kamala, Vieira, José Luiz F, Watson, James A, Zuluaga-Idarraga, Lina M, White, Nicholas J, Guerin, Philippe J, Simpson, Julie A, and Price, Ric N
- Published
- 2024
- Full Text
- View/download PDF
3. Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis
- Author
-
Adhikari, Bipin, Alam, Mohammad Shafiul, Anstey, Nicholas M, Assefa, Ashenafi, Boyd, Sarah C, Chau, Nguyen Hoang, Day, Nicholas PJ, Degaga, Tamiru Shibiru, Dondorp, Arjen M, Ferreira, Marcelo Urbano, Ghimire, Prakash, Green, Justin A, Khan, Wasif Ali, Koh, Gavin CKW, Mekuria, Asrat Hailu, Naadim, Mohammad Nader, Nelwan, Erni J, Nosten, Francois, Pasaribu, Ayodhia Pitaloka, Price, David J, Stepniewska, Kasia, von Seidlein, Lorenz, William, Timothy, Woodrow, Charles J, Woyessa, Adugna, Rajasekhar, Megha, Simpson, Julie A, Ley, Benedikt, Edler, Peta, Chu, Cindy S, Abreha, Tesfay, Awab, Ghulam R, Baird, J Kevin, Bancone, Germana, Barber, Bridget E, Grigg, Matthew J, Hwang, Jimee, Karunajeewa, Harin, Lacerda, Marcus V G, Ladeia-Andrade, Simone, Llanos-Cuentas, Alejandro, Pukrittayakamee, Sasithon, Rijal, Komal R, Saravu, Kavitha, Sutanto, Inge, Taylor, Walter R J, Thriemer, Kamala, Watson, James A, Guerin, Philippe J, White, Nicholas J, Price, Ric N, and Commons, Robert J
- Published
- 2024
- Full Text
- View/download PDF
4. A molecular barcode and web-based data analysis tool to identify imported Plasmodium vivax malaria
- Author
-
Trimarsanto, Hidayat, Amato, Roberto, Pearson, Richard D., Sutanto, Edwin, Noviyanti, Rintis, Trianty, Leily, Marfurt, Jutta, Pava, Zuleima, Echeverry, Diego F., Lopera-Mesa, Tatiana M., Montenegro, Lidia M., Tobón-Castaño, Alberto, Grigg, Matthew J., Barber, Bridget, William, Timothy, Anstey, Nicholas M., Getachew, Sisay, Petros, Beyene, Aseffa, Abraham, Assefa, Ashenafi, Rahim, Awab G., Chau, Nguyen H., Hien, Tran T., Alam, Mohammad S., Khan, Wasif A., Ley, Benedikt, Thriemer, Kamala, Wangchuck, Sonam, Hamedi, Yaghoob, Adam, Ishag, Liu, Yaobao, Gao, Qi, Sriprawat, Kanlaya, Ferreira, Marcelo U., Laman, Moses, Barry, Alyssa, Mueller, Ivo, Lacerda, Marcus V. G., Llanos-Cuentas, Alejandro, Krudsood, Srivicha, Lon, Chanthap, Mohammed, Rezika, Yilma, Daniel, Pereira, Dhelio B., Espino, Fe E. J., Chu, Cindy S., Vélez, Iván D., Namaik-larp, Chayadol, Villegas, Maria F., Green, Justin A., Koh, Gavin, Rayner, Julian C., Drury, Eleanor, Gonçalves, Sónia, Simpson, Victoria, Miotto, Olivo, Miles, Alistair, White, Nicholas J., Nosten, Francois, Kwiatkowski, Dominic P., Price, Ric N., and Auburn, Sarah
- Published
- 2022
- Full Text
- View/download PDF
5. Who is protected? Determinants of hepatitis B infant vaccination completion among a prospective cohort of migrant workers in Thailand during the COVID-19 pandemic
- Author
-
Gilder, Mary Ellen, Pateekhum, Chanapat, Hashmi, Ahmar, Aramrat, Chanchanok, Aung, Ko Ko, Miket, Wimon, Chu, Cindy S., Win, December, Bierhoff, Marieke, Wiwattanacharoen, Wichuda, Jiraporncharoen, Wichuda, Angkurawaranon, Chaisiri, and McGready, Rose
- Published
- 2022
- Full Text
- View/download PDF
6. Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria
- Author
-
Chu, Cindy S., Phyo, Aung Pyae, Lwin, Khin Maung, Win, Htun Htun, San, Thida, Aung, Aye Aye, Raksapraidee, Rattanaporn, Carrara, Verena I., Bancone, Germana, Watson, James, Moore, Kerryn A., Wiladphaingern, Jacher, Proux, Stéphane, Sriprawat, Kanlaya, Winterberg, Markus, Cheah, Phaik Yeong, Chue, Amy L., Tarning, Joel, Imwong, Mallika, Nosten, François, and White, Nicholas J.
- Published
- 2018
7. Primaquine Pharmacokinetics in Lactating Women and Breastfed Infant Exposures
- Author
-
Gilder, Mary Ellen, Hanpithakphong, Warunee, Hoglund, Richard M., Tarning, Joel, Win, Htun Htun, Hilda, Naw, Chu, Cindy S., Bancone, Germana, Carrara, Verena I., Singhasivanon, Pratap, White, Nicholas J., Nosten, François, and McGready, Rose
- Published
- 2018
8. The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis
- Author
-
Commons, Robert J, Simpson, Julie A, Thriemer, Kamala, Humphreys, Georgina S, Abreha, Tesfay, Alemu, Sisay G, Añez, Arletta, Anstey, Nicholas M, Awab, Ghulam R, Baird, J Kevin, Barber, Bridget E, Borghini-Fuhrer, Isabelle, Chu, Cindy S, D'Alessandro, Umberto, Dahal, Prabin, Daher, André, de Vries, Peter J, Erhart, Annette, Gomes, Margarete S M, Gonzalez-Ceron, Lilia, Grigg, Matthew J, Heidari, Aliehsan, Hwang, Jimee, Kager, Piet A, Ketema, Tsige, Khan, Wasif A, Lacerda, Marcus V G, Leslie, Toby, Ley, Benedikt, Lidia, Kartini, Monteiro, Wuelton M, Nosten, Francois, Pereira, Dhelio B, Phan, Giao T, Phyo, Aung P, Rowland, Mark, Saravu, Kavitha, Sibley, Carol H, Siqueira, André M, Stepniewska, Kasia, Sutanto, Inge, Taylor, Walter R J, Thwaites, Guy, Tran, Binh Q, Tran, Hien T, Valecha, Neena, Vieira, José Luiz F, Wangchuk, Sonam, William, Timothy, Woodrow, Charles J, Zuluaga-Idarraga, Lina, Guerin, Philippe J, White, Nicholas J, and Price, Ric N
- Published
- 2018
- Full Text
- View/download PDF
9. Response to comment on 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis'.
- Author
-
Watson, James A., Commons, Robert J., Tarning, Joel, Simpson, Julie A., Llanos Cuentas, Alejandro, Lacerda, Marcus V. G., Green, Justin A., Koh, Gavin C. K. W., Chu, Cindy S., Nosten, François H., Price, Richard N., Day, Nicholas P. J., and White, Nicholas J.
- Published
- 2024
- Full Text
- View/download PDF
10. Primaquine in glucose-6-phosphate dehydrogenase deficiency: an adaptive pharmacometric assessment of ascending dose regimens in healthy volunteers.
- Author
-
Sasithon Pukrittayakamee, Podjanee Jittamala, Watson, James A., Borimas Hanboonkunupakarn, Pawanrat Leungsinsiri, Kittiyod Poovorawan, Kesinee Chotivanich, Germana Bancone, Chu, Cindy S., Mallika Imwong, Day, Nicholas P. J., Taylor, Walter R. J., and White, Nicholas J.
- Published
- 2024
- Full Text
- View/download PDF
11. Asian G6PD-Mahidol Reticulocytes Sustain Normal Plasmodium Vivax Development
- Author
-
Bancone, Germana, Malleret, Benoit, Suwanarusk, Rossarin, Chowwiwat, Nongnud, Chu, Cindy S., McGready, Rose, Rénia, Laurent, Nosten, François, and Russell, Bruce
- Published
- 2017
12. Immunization Coverage in Migrant School Children Along the Thailand-Myanmar Border
- Author
-
Kaji, Aiko, Parker, Daniel M., Chu, Cindy S., Thayatkawin, Wipa, Suelaor, Jiraporn, Charatrueangrongkun, Rachai, Salathibuppha, Kloloi, Nosten, Francois H., and McGready, Rose
- Published
- 2016
13. Vivax malaria in pregnancy and lactation: a long way to health equity
- Author
-
Brummaier, Tobias, Gilder, Mary Ellen, Gornsawun, Gornpan, Chu, Cindy S., Bancone, Germana, Pimanpanarak, Mupawjay, Chotivanich, Kesinee, Nosten, François, and McGready, Rose
- Published
- 2020
- Full Text
- View/download PDF
14. Resolving the cause of recurrent Plasmodium vivax malaria probabilistically
- Author
-
Taylor, Aimee R., Watson, James A., Chu, Cindy S., Puaprasert, Kanokpich, Duanguppama, Jureeporn, Day, Nicholas P. J., Nosten, Francois, Neafsey, Daniel E., Buckee, Caroline O., Imwong, Mallika, and White, Nicholas J.
- Published
- 2019
- Full Text
- View/download PDF
15. Molecular characterization and mapping of glucose-6-phosphate dehydrogenase (G6PD) mutations in the Greater Mekong Subregion
- Author
-
Bancone, Germana, Menard, Didier, Khim, Nimol, Kim, Saorin, Canier, Lydie, Nguong, Chea, Phommasone, Koukeo, Mayxay, Mayfong, Dittrich, Sabine, Vongsouvath, Malavanh, Fievet, Nadine, Le Hesran, Jean-Yves, Briand, Valerie, Keomany, Sommay, Newton, Paul N., Gorsawun, Gornpan, Tardy, Kaelan, Chu, Cindy S., Rattanapalroj, Orpreeya, Dong, Le Thanh, Quang, Huynh Hong, Tam-Uyen, Nguyen, Thuy-Nhien, Nguyen, Hien, Tran Tinh, Kalnoky, Michael, and Nosten, Francois
- Published
- 2019
- Full Text
- View/download PDF
16. Clinical performance validation of the STANDARD G6PD test: A multi-country pooled analysis.
- Author
-
Adissu, Wondimagegn, Brito, Marcelo, Garbin, Eduardo, Macedo, Marcela, Monteiro, Wuelton, Mukherjee, Sandip Kumar, Myburg, Jane, Alam, Mohammad Shafiul, Bancone, Germana, Bansil, Pooja, Pal, Sampa, Sharma, Abhijit, Zobrist, Stephanie, Bryan, Andrew, Chu, Cindy S., Das, Santasabuj, Domingo, Gonzalo J., Hann, Amanda, Kublin, James, and Lacerda, Marcus V. G.
- Subjects
GLUCOSE-6-phosphate dehydrogenase deficiency ,PERFORMANCE standards ,ERYTHROCYTES ,BLOOD cell count ,DRUG accessibility ,GLUCOSE-6-phosphate dehydrogenase - Abstract
Introduction: Screening for G6PD deficiency can inform disease management including malaria. Treatment with the antimalarial drugs primaquine and tafenoquine can be guided by point-of-care testing for G6PD deficiency. Methods and findings: Data from similar clinical studies evaluating the performance of the STANDARD G6PD Test (SD Biosensor, South Korea) conducted in Bangladesh, Brazil, Ethiopia, India, Thailand, the United Kingdom, and the United States were pooled. Test performance was assessed in a retrospective analysis on capillary and venous specimens. All study sites used spectrophotometry for reference G6PD testing, and either the HemoCue or complete blood count for reference hemoglobin measurement. The sensitivity of the STANDARD G6PD Test using the manufacturer thresholds for G6PD deficient and intermediate cases in capillary specimens from 4212 study participants was 100% (95% Confidence Interval (CI): 97.5%–100%) for G6PD deficient cases with <30% activity and 77% (95% CI 66.8%–85.4%) for females with intermediate activity between 30%–70%. Specificity was 98.1% (95% CI 97.6%–98.5%) and 92.8% (95% CI 91.6%–93.9%) for G6PD deficient individuals and intermediate females, respectively. Out of 20 G6PD intermediate females with false normal results, 12 had activity levels >60% on the reference assay. The negative predictive value for females with G6PD activity >60% was 99.6% (95% CI 99.1%–99.8%) on capillary specimens. Sensitivity among 396 P. vivax malaria cases was 100% (69.2%–100.0%) for both deficient and intermediate cases. Across the full dataset, 37% of those classified as G6PD deficient or intermediate resulted from true normal cases. Despite this, over 95% of cases would receive correct treatment with primaquine, over 87% of cases would receive correct treatment with tafenoquine, and no true G6PD deficient cases would be treated inappropriately based on the result of the STANDARD G6PD Test. Conclusions: The STANDARD G6PD Test enables safe access to drugs which are contraindicated for individuals with G6PD deficiency. Operational considerations will inform test uptake in specific settings. Author summary: The glucose-6-phosphate dehydrogenase (G6PD) enzyme helps red blood cells work properly. When the body does not have enough of this enzyme and is exposed to oxidative challenges, including certain foods and medicines, red blood cells break down faster than they are made, causing hemolytic anemia. Diagnostics tools for this common condition have been limited but now, new point of care tests are available that can screen more people who are unable to access laboratory services. This is particularly important for the treatment of vivax malaria, where the only treatment options require G6PD screening before administration. This research provides an evaluation of the diagnostic performance of one such tool, the STANDARD G6PD Test (SD Biosensor, South Korea), based on extensive data from multiple studies. These data show that the test can be used to safely identify people with G6PD deficiency, which will help ensure they do not receive contraindicated medicines. The research also provides specific estimates about how this test may impact malaria case management and treatment options. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. Severe Falciparum and Vivax Malaria on the Thailand-Myanmar Border: A Review of 1503 Cases.
- Author
-
Chu, Cindy S, Stolbrink, Marie, Stolady, Daniel, Saito, Makoto, Beau, Candy, Choun, Kan, Wah, Tha Gay, Mu, Ne, Htoo, Klay, Nu, Be, Keereevijit, Arunrot, Wiladpaingern, Jacher, Carrara, Verena, Phyo, Aung Pyae, Lwin, Khin Maung, Luxemburger, Christine, Proux, Stephane, Charunwatthana, Prakaykaew, McGready, Rose, and White, Nicholas J
- Subjects
- *
PUBLIC health surveillance , *PATIENTS , *MALARIA , *SEPSIS , *SEVERITY of illness index , *HOSPITAL admission & discharge , *HOSPITAL care , *DESCRIPTIVE statistics , *RESEARCH funding , *DISEASE risk factors - Abstract
Background The northwestern border of Thailand is an area of low seasonal malaria transmission. Until recent successful malaria elimination activities, malaria was a major cause of disease and death. Historically the incidences of symptomatic Plasmodium falciparum and Plasmodium vivax malaria were approximately similar. Methods All malaria cases managed in the Shoklo Malaria Research Unit along the Thailand-Myanmar border between 2000 and 2016 were reviewed. Results There were 80 841 consultations for symptomatic P. vivax and 94 467 for symptomatic P. falciparum malaria. Overall, 4844 (5.1%) patients with P. falciparum malaria were admitted to field hospitals, of whom 66 died, compared with 278 (0.34%) with P. vivax malaria, of whom 4 died (3 had diagnoses of sepsis, so the contribution of malaria to their fatal outcomes is uncertain). Applying the 2015 World Health Organization severe malaria criteria, 68 of 80 841 P. vivax admissions (0.08%) and 1482 of 94 467 P. falciparum admissions (1.6%) were classified as severe. Overall, patients with P. falciparum malaria were 15 (95% confidence interval, 13.2–16.8) times more likely than those with P. vivax malaria to require hospital admission, 19 (14.6–23.8) times more likely to develop severe malaria, and ≥14 (5.1–38.7) times more likely to die. Conclusions In this area, both P. falciparum and P. vivax infections were important causes of hospitalization, but life-threatening P. vivax illness was rare. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. The prevention and treatment of Plasmodium vivax malaria
- Author
-
Chu, Cindy S. and White, Nicholas J.
- Subjects
Plasmodium vivax -- Health aspects ,Antimalarials -- Dosage and administration ,Malaria -- Causes of -- Prevention -- Drug therapy ,Biological sciences - Abstract
Author(s): Cindy S. Chu 1,2,*, Nicholas J. White 1,3 Summary points The worldwide burden of Plasmodium vivax malaria has more than halved from an estimated 17.3 to 6.5 million cases [...]
- Published
- 2021
- Full Text
- View/download PDF
19. Unambiguous determination of Plasmodium vivax reticulocyte invasion by flow cytometry
- Author
-
Cho, Jee-Sun, Russell, Bruce, Kosasaivee, Varakorn, Zhang, Rou, Colin, Yves, Bertrand, Olivier, Chandramohanadas, Rajesh, Chu, Cindy S., Nosten, Francois, Renia, Laurent, and Malleret, Benoit
- Published
- 2016
- Full Text
- View/download PDF
20. The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis
- Author
-
Commons, Robert J., Simpson, Julie A., Thriemer, Kamala, Chu, Cindy S., Douglas, Nicholas M., Abreha, Tesfay, Alemu, Sisay G., Añez, Arletta, Anstey, Nicholas M., Aseffa, Abraham, Assefa, Ashenafi, Awab, Ghulam R., Baird, J. Kevin, Barber, Bridget E., Borghini-Fuhrer, Isabelle, D’Alessandro, Umberto, Dahal, Prabin, Daher, André, de Vries, Peter J., Erhart, Annette, Gomes, Margarete S. M., Grigg, Matthew J., Hwang, Jimee, Kager, Piet A., Ketema, Tsige, Khan, Wasif A., Lacerda, Marcus V. G., Leslie, Toby, Ley, Benedikt, Lidia, Kartini, Monteiro, Wuelton M., Pereira, Dhelio B., Phan, Giao T., Phyo, Aung P., Rowland, Mark, Saravu, Kavitha, Sibley, Carol H., Siqueira, André M., Stepniewska, Kasia, Taylor, Walter R. J., Thwaites, Guy, Tran, Binh Q., Hien, Tran T., Vieira, José Luiz F., Wangchuk, Sonam, Watson, James, William, Timothy, Woodrow, Charles J., Nosten, Francois, Guerin, Philippe J., White, Nicholas J., and Price, Ric N.
- Published
- 2019
- Full Text
- View/download PDF
21. Variability in white blood cell count during uncomplicated malaria and implications for parasite density estimation: a WorldWide Antimalarial Resistance Network individual patient data meta-analysis.
- Author
-
WorldWide Antimalarial Resistance Network White Blood Cell Count in Malaria Study Group, Wynberg, Elke, Commons, Robert J., Humphreys, Georgina, Ashurst, Hazel, Burrow, Rebekah, Adjei, George O., Adjuik, Martin, Anstey, Nicholas M., Anvikar, Anup, Baird, Kevin J., Barber, Bridget E., Barennes, Hubert, Baudin, Elisabeth, Bell, David J., Bethell, Delia, Binh, Tran Quang, Borghini-Fuhrer, Isabelle, Chu, Cindy S., and Daher, Andre
- Subjects
LEUKOCYTE count ,PLASMODIUM ,LEUCOCYTES ,RESOURCE-limited settings ,DATA libraries ,TRYPANOSOMA - Abstract
Background: The World Health Organization (WHO) recommends that when peripheral malarial parasitaemia is quantified by thick film microscopy, an actual white blood cell (WBC) count from a concurrently collected blood sample is used in calculations. However, in resource-limited settings an assumed WBC count is often used instead. The aim of this study was to describe the variability in WBC count during acute uncomplicated malaria, and estimate the impact of using an assumed value of WBC on estimates of parasite density and clearance. Methods: Uncomplicated malaria drug efficacy studies that measured WBC count were selected from the WorldWide Antimalarial Resistance Network data repository for an individual patient data meta-analysis of WBC counts. Regression models with random intercepts for study-site were used to assess WBC count variability at presentation and during follow-up. Inflation factors for parasitaemia density, and clearance estimates were calculated for methods using assumed WBC counts (8000 cells/µL and age-stratified values) using estimates derived from the measured WBC value as reference. Results: Eighty-four studies enrolling 27,656 patients with clinically uncomplicated malaria were included. Geometric mean WBC counts (× 1000 cells/µL) in age groups < 1, 1–4, 5–14 and ≥ 15 years were 10.5, 8.3, 7.1, 5.7 and 7.5, 7.0, 6.5, 6.0 for individuals with falciparum (n = 24,978) and vivax (n = 2678) malaria, respectively. At presentation, higher WBC counts were seen among patients with higher parasitaemia, severe anaemia and, for individuals with vivax malaria, in regions with shorter regional relapse periodicity. Among falciparum malaria patients, using an assumed WBC count of 8000 cells/µL resulted in parasite density underestimation by a median (IQR) of 26% (4–41%) in infants < 1 year old but an overestimation by 50% (16–91%) in adults aged ≥ 15 years. Use of age-stratified assumed WBC values removed systematic bias but did not improve precision of parasitaemia estimation. Imprecision of parasite clearance estimates was only affected by the within-patient WBC variability over time, and remained < 10% for 79% of patients. Conclusions: Using an assumed WBC value for parasite density estimation from a thick smear may lead to underdiagnosis of hyperparasitaemia and could adversely affect clinical management; but does not result in clinically consequential inaccuracies in the estimation of the prevalence of prolonged parasite clearance and artemisinin resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. Plasmodium vivax: restricted tropism and rapid remodeling of CD71-positive reticulocytes
- Author
-
Malleret, Benoit, Li, Ang, Zhang, Rou, Tan, Kevin S.W., Suwanarusk, Rossarin, Claser, Carla, Cho, Jee Sun, Koh, Esther Geok Liang, Chu, Cindy S., Pukrittayakamee, Sasithon, Ng, Mah Lee, Ginhoux, Florent, Ng, Lai Guan, Lim, Chwee Teck, Nosten, François, Snounou, Georges, Rénia, Laurent, and Russell, Bruce
- Published
- 2015
- Full Text
- View/download PDF
23. The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis
- Author
-
Commons, Robert J., Simpson, Julie A., Thriemer, Kamala, Abreha, Tesfay, Adam, Ishag, Anstey, Nicholas M., Assefa, Ashenafi, Awab, Ghulam R., Baird, J. Kevin, Barber, Bridget E., Chu, Cindy S., Dahal, Prabin, Daher, André, Davis, Timothy M. E., Dondorp, Arjen M., Grigg, Matthew J., Humphreys, Georgina S., Hwang, Jimee, Karunajeewa, Harin, Laman, Moses, Lidia, Kartini, Moore, Brioni R., Mueller, Ivo, Nosten, Francois, Pasaribu, Ayodhia P., Pereira, Dhelio B., Phyo, Aung P., Poespoprodjo, Jeanne R., Sibley, Carol H., Stepniewska, Kasia, Sutanto, Inge, Thwaites, Guy, Hien, Tran T., White, Nicholas J., William, Timothy, Woodrow, Charles J., Guerin, Philippe J., and Price, Ric N.
- Subjects
EPUB (Standard) ,Artemisinin -- Analysis ,Primaquine -- Analysis ,Medical research -- Analysis ,Malaria -- Analysis ,Recurrence (Disease) ,Prophylaxis ,Retirement benefits ,Hemoglobins ,Antimalarials ,Biological sciences ,World Health Organization - Abstract
Background Artemisinin-based combination therapy (ACT) is recommended for uncomplicated Plasmodium vivax malaria in areas of emerging chloroquine resistance. We undertook a systematic review and individual patient data meta-analysis to compare the efficacies of dihydroartemisinin-piperaquine (DP) and artemether-lumefantrine (AL) with or without primaquine (PQ) on the risk of recurrent P. vivax. Methods and findings Clinical efficacy studies of uncomplicated P. vivax treated with DP or AL and published between January 1, 2000, and January 31, 2018, were identified by conducting a systematic review registered with the International Prospective Register of Systematic Reviews (PROSPERO): CRD42016053310. Investigators of eligible studies were invited to contribute individual patient data that were pooled using standardised methodology. The effect of mg/kg dose of piperaquine/lumefantrine, ACT administered, and PQ on the rate of P. vivax recurrence between days 7 and 42 after starting treatment were investigated by Cox regression analyses according to an a priori analysis plan. Secondary outcomes were the risk of recurrence assessed on days 28 and 63. Nineteen studies enrolling 2,017 patients were included in the analysis. The risk of recurrent P. vivax at day 42 was significantly higher in the 384 patients treated with AL alone (44.0%, 95% confidence interval [CI] 38.7-49.8) compared with the 812 patients treated with DP alone (9.3%, 95% CI 7.1-12.2): adjusted hazard ratio (AHR) 12.63 (95% CI 6.40-24.92), p < 0.001. The rates of recurrence assessed at days 42 and 63 were associated inversely with the dose of piperaquine: AHRs (95% CI) for every 5-mg/kg increase 0.63 (0.48-0.84), p = 0.0013 and 0.83 (0.73-0.94), p = 0.0033, respectively. The dose of lumefantrine was not significantly associated with the rate of recurrence (1.07 for every 5-mg/kg increase, 95% CI 0.99-1.16, p = 0.0869). In a post hoc analysis, in patients with symptomatic recurrence after AL, the mean haemoglobin increased 0.13 g/dL (95% CI 0.01-0.26) for every 5 days that recurrence was delayed, p = 0.0407. Coadministration of PQ reduced substantially the rate of recurrence assessed at day 42 after AL (AHR = 0.20, 95% CI 0.10-0.41, p < 0.001) and at day 63 after DP (AHR = 0.08, 95% CI 0.01-0.70, p = 0.0233). Results were limited by follow-up of patients to 63 days or less and nonrandomised treatment groups. Conclusions In this study, we observed the risk of P. vivax recurrence at day 42 to be significantly lower following treatment with DP compared with AL, reflecting the longer period of post-treatment prophylaxis; this risk was reduced substantially by coadministration with PQ. We found that delaying P. vivax recurrence was associated with a small but significant improvement in haemoglobin. These results highlight the benefits of PQ radical cure and also the provision of blood-stage antimalarial agents with prolonged post-treatment prophylaxis., Author(s): Robert J. Commons 1,2,*, Julie A. Simpson 3, Kamala Thriemer 1, Tesfay Abreha 4, Ishag Adam 5, Nicholas M. Anstey 1, Ashenafi Assefa 6, Ghulam R. Awab 7,8, J. [...]
- Published
- 2019
- Full Text
- View/download PDF
24. Cytochemical flow analysis of intracellular G6PD and aggregate analysis of mosaic G6PD expression
- Author
-
Kalnoky, Michael, Bancone, Germana, Kahn, Maria, Chu, Cindy S., Chowwiwat, Nongnud, Wilaisrisak, Pornpimon, Pal, Sampa, LaRue, Nicole, Leader, Brandon, Nosten, Francois, and Domingo, Gonzalo J.
- Published
- 2018
- Full Text
- View/download PDF
25. Population heterogeneity in Plasmodium vivax relapse risk.
- Author
-
Stadler, Eva, Cromer, Deborah, Mehra, Somya, Adekunle, Adeshina I., Flegg, Jennifer A., Anstey, Nicholas M., Watson, James A., Chu, Cindy S., Mueller, Ivo, Robinson, Leanne J., Schlub, Timothy E., Davenport, Miles P., and Khoury, David S.
- Subjects
PLASMODIUM vivax ,HETEROGENEITY ,BORDERLANDS ,INFECTIOUS disease transmission ,INDIVIDUAL differences - Abstract
A key characteristic of Plasmodium vivax parasites is their ability to adopt a latent liver-stage form called hypnozoites, able to cause relapse of infection months or years after a primary infection. Relapses of infection through hypnozoite activation are a major contributor to blood-stage infections in P vivax endemic regions and are thought to be influenced by factors such as febrile infections which may cause temporary changes in hypnozoite activation leading to 'temporal heterogeneity' in reactivation risk. In addition, immunity and variation in exposure to infection may be longer-term characteristics of individuals that lead to 'population heterogeneity' in hypnozoite activation. We analyze data on risk of P vivax in two previously published data sets from Papua New Guinea and the Thailand-Myanmar border region. Modeling different mechanisms of reactivation risk, we find strong evidence for population heterogeneity, with 30% of patients having almost 70% of all P vivax infections. Model fitting and data analysis indicates that individual variation in relapse risk is a primary source of heterogeneity of P vivax risk of recurrences. Trial Registration: ClinicalTrials.gov NCT01640574, NCT01074905, NCT02143934. Author summary: Despite elimination efforts, malaria continues to be a public health burden world-wide. Partially due to its ability to remain dormant in the liver for weeks or months, the malaria parasite Plasmodium vivax has not responded well to elimination efforts. These dormant parasites may reactivate and thereby cause disease and contribute to further transmission of the disease. Though it is often assumed that reactivations of dormant P vivax parasites occur at a constant rate, it has also been proposed that there is a time of increased risk of reactivation ('temporal heterogeneity') and there may be differences in individual's reactivation risks ('population heterogeneity'). We created models for constant reactivations, temporal heterogeneity, and population heterogeneity which we use to analyse data of P vivax malaria events from the Thailand-Myanmar border region and Papua New Guinea. We find strong evidence for population heterogeneity as a major determinant of reactivation patterns. Further analysis of the data suggests that spatial heterogeneity in exposure to infectious mosquito bites is a potential contributor to this heterogeneity. Thus, we find that population heterogeneity plays an important role in the overall epidemiology of P vivax recurrences. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis.
- Author
-
Watson, James A., Commons, Robert J., Tarning, Joel, Simpson, Julie A., Cuentas, Alejandro Llanos, Lacerda, Marcus V. G., Green, Justin A., Koh, Gavin C. K. W., Chu, Cindy S., Nosten, François H., Price, Richard N., Day, Nicholas P. J., and White, Nicholas J.
- Published
- 2022
- Full Text
- View/download PDF
27. The role of point-of-care tests in antibiotic stewardship for urinary tract infections in a resource-limited setting on the Thailand–Myanmar border
- Author
-
Chalmers, Lauren, Cross, Jessica, Chu, Cindy S., Phyo, Aung Pyae, Trip, Margreet, Ling, Clare, Carrara, Verena, Watthanaworawit, Wanitda, Keereecharoen, Lily, Hanboonkunupakarn, Borimas, Nosten, François, and McGready, Rose
- Published
- 2015
- Full Text
- View/download PDF
28. Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens
- Author
-
Chu, Cindy S., Bancone, Germana, Moore, Kerryn A., Win, Htun Htun, Thitipanawan, Niramon, Po, Christina, Chowwiwat, Nongnud, Raksapraidee, Rattanaporn, Wilairisak, Pornpimon, Phyo, Aung Pyae, Keereecharoen, Lily, Proux, Stéphane, Charunwatthana, Prakaykaew, Nosten, François, and White, Nicholas J.
- Subjects
Hemolysis and hemolysins -- Diagnosis ,Primaquine -- Usage -- Physiological aspects ,Malaria -- Physiological aspects -- Drug therapy ,Biological sciences - Abstract
Background Radical cure of Plasmodium vivax malaria with 8-aminoquinolines (primaquine or tafenoquine) is complicated by haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD heterozygous females, because of individual variation in the pattern of X-chromosome inactivation (Lyonisation) in erythroid cells, may have low G6PD activity in the majority of their erythrocytes, yet are usually reported as G6PD 'normal' by current phenotypic screening tests. Their haemolytic risk when treated with 8-aminoquinolines has not been well characterized. Methods and Findings In a cohort study nested within a randomised clinical trial that compared different treatment regimens for P. vivax malaria, patients with a normal standard NADPH fluorescent spot test result ([greater-than or equivalent to]30%-40% of normal G6PD activity) were randomised to receive 3 d of chloroquine or dihydroartemisinin-piperaquine in combination with primaquine, either the standard high dose of 0.5 mg base/kg/day for 14 d or a higher dose of 1 mg base/kg/d for 7 d. Patterns of haemolysis were compared between G6PD wild-type and G6PD heterozygous female participants. Between 21 February 2012 and 04 July 2014, 241 female participants were enrolled, of whom 34 were heterozygous for the G6PD Mahidol variant. Haemolysis was substantially greater and a larger proportion of participants reached the threshold of clinically significant haemolysis (fractional haematocrit reduction >25%) in G6PD heterozygotes taking the higher (7 d) primaquine dose (9/17 [53%]) compared with G6PD heterozygotes taking the standard high (14 d) dose (2/16 [13%]; p = 0.022). In heterozygotes, the mean fractional haematocrit reductions were correspondingly greater with the higher primaquine dose (7-d regimen): -20.4% (95% CI -26.0% to -14.8%) (nadir on day 5) compared with the standard high (14 d) dose: -13.1% (95% CI -17.6% to -8.6%) (nadir day 6). Two heterozygotes taking the higher (7 d) primaquine dose required blood transfusion. In wild-type participants, mean haematocrit reductions were clinically insignificant and similar with both doses: -5.8 (95% CI -7.2% to -4.4%) (nadir day 3) compared with -5.5% (95% CI -7.4% to -3.7%) (nadir day 4), respectively. Limitations to this nested cohort study are that the primary objective of the trial was designed to measure efficacy and not haemolysis in relation to G6PD genotype and that the heterozygote groups were small. Conclusion Higher daily doses of primaquine have the potential to cause clinically significant haemolysis in G6PD heterozygous females who are reported as phenotypically normal with current point of care tests. Trial Registration ClinicalTrials.gov NCT01640574., Author(s): Cindy S. Chu 1,2,*, Germana Bancone 1,2, Kerryn A. Moore 3,4, Htun Htun Win 1, Niramon Thitipanawan 1, Christina Po 1, Nongnud Chowwiwat 1, Rattanaporn Raksapraidee 1, Pornpimon Wilairisak [...]
- Published
- 2017
- Full Text
- View/download PDF
29. Declining Burden of Plasmodium vivax in a Population in Northwestern Thailand from 1995 to 2016 before Comprehensive Primaquine Prescription for Radical Cure.
- Author
-
Chu, Cindy S., Carrara, Verena I., Parker, Daniel M., Proux, Stéphane, Charunwatthana, Prakaykaew, McGready, Rose, and Nosten, François
- Published
- 2020
- Full Text
- View/download PDF
30. Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
- Author
-
Chu, Cindy S, Phyo, Aung Pyae, Turner, Claudia, Win, Htun Htun, Poe, Naw Pet, Yotyingaphiram, Widi, Thinraow, Suradet, Wilairisak, Pornpimon, Raksapraidee, Rattanaporn, Carrara, Verena I, Paw, Moo Kho, Wiladphaingern, Jacher, Proux, Stéphane, Bancone, Germana, Sriprawat, Kanlaya, Lee, Sue J, Jeeyapant, Atthanee, Watson, James, Tarning, Joel, and Imwong, Mallika
- Subjects
- *
DRUG therapy for malaria , *CHLOROQUINE , *CLINICAL trials , *CONFIDENCE intervals , *DRUG side effects , *HEMATOCRIT , *PRIMAQUINE , *RESEARCH funding , *TIME , *DISEASE relapse , *TREATMENT effectiveness , *GENETIC carriers , *DESCRIPTIVE statistics , *THERAPEUTICS - Abstract
Background Primaquine is necessary for the radical cure of Plasmodium vivax malaria, but the optimum duration of treatment and best partner drug are uncertain. A randomized controlled trial was performed to compare the tolerability and radical curative efficacy of 7-day versus 14-day high-dose primaquine regimens (total dose 7mg/kg) with either chloroquine or dihydroartemisinin-piperaquine. Methods Patients with uncomplicated P. vivax malaria on the Thailand-Myanmar border were randomized to either chloroquine (25mg base/kg) or dihydroartemisinin-piperaquine (dihydroartemisinin 7mg/kg and piperaquine 55mg/kg) plus primaquine, either 0.5 mg/kg/day for 14 days or 1 mg/kg/day for 7 days. Adverse events within 42 days and 1-year recurrence rates were compared and their relationship with day 6 drug concentrations assessed. Results Between February 2012 and July 2014, 680 patients were enrolled. P. vivax recurrences (all after day 35) occurred in 80/654 (12%) patients; there was no difference between treatments. Compared to the 7-day primaquine groups the pooled relative risk of recurrence in the 14-day groups was 1.15 (95% confidence interval 0.7 to 1.8). Hematocrit reductions were clinically insignificant except in G6PD female heterozygotes, 2 of whom had hematocrit reductions to <23% requiring blood transfusion. Conclusion Radical cure should be deployed more widely. The radical curative efficacy in vivax malaria of 7-day high-dose primaquine is similar to the standard 14-day high-dose regimen. Chloroquine and dihydroartemisinin-piperaquine are both highly effective treatments of the blood stage infection. Quantitative point of care G6PD testing would ensure safe use of the 7-day high-dose primaquine regimen in G6PD heterozygous females. Clinical Trials Registration NCT01640574. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
31. Maternal Hepatitis B Infection Burden, Comorbidity and Pregnancy Outcome in a Low-Income Population on the Myanmar-Thailand Border: A Retrospective Cohort Study.
- Author
-
Bierhoff, Marieke, Angkurawaranon, Chaisiri, Myat Min, Aung, Gilder, Mary Ellen, Win Tun, Nay, Keereevijitt, Arunrot, Kyi Win, Aye, Win, Elsi, Carrara, Verena Ilona, Brummaier, Tobias, Chu, Cindy S., Thielemans, Laurence, Sriprawat, Kanlaya, Hanboonkunupakarn, Borimas, Rijken, Marcus, Nosten, François, Vugt, Michele van, and McGready, Rose
- Abstract
Objectives. Hepatitis B virus (HBV) was believed to have minimal impact on pregnancy outcomes apart from the risk of perinatal transmission. In more recent years, there have been reports of adverse associations, most consistently preterm birth (PTB), but this is in the context of high rates of caesarean section. The aim of this study was to explore the association of HBV on pregnancy outcomes in marginalized, low-income populations on the Myanmar-Thailand border. Methods. HBsAg positive (+) point of care rapid detection tests results were confirmed by immunoassays. Women with a confirmed HBsAg status, HIV- and syphilis-negative at first antenatal care screening, singleton fetus and known pregnancy outcome (Aug-2012 to Dec-2016) were included. Logistic regression analysis was used to evaluate associations between HBV group (controls HBsAg negative, HBsAg+/HBeAg-, or HBsAg+/HBeAg+) and pregnancy outcome and comorbidity. Results. Most women were tested, 15,046/15,114 (99.6%) for HBV. The inclusion criteria were not met for 4,089/15,046 (27.2%) women due mainly to unavailability of pregnancy outcome and nonconfirmation of HBsAg+. In evaluable women 687/11,025 (6.2%) were HBsAg+, with 476/11,025 (4.3%) HBsAg+/HBeAg- and 211/11,025 (1.9%) were HBsAg+/HBeAg+. The caesarean section rate was low at 522/8,963 (5.8%). No significant associations were observed between pregnancy comorbidities or adverse pregnancy outcomes and HBV status. Conclusions. The results highlight the disease burden of HBV in women on the Myanmar-Thailand border and support original reports of a lack of significant associations with HBsAg+ irrespective of HBeAg status, for comorbidity, and pregnancy outcomes in deliveries supervised by skilled birth attendants. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
32. Evaluation of a Novel Quantitative Test for Glucose-6-Phosphate Dehydrogenase Deficiency: Bringing Quantitative Testing for Glucose-6-Phosphate Dehydrogenase Deficiency Closer to the Patient.
- Author
-
Pal, Sampa, Bansil, Pooja, Bancone, Germana, Hrutkay, Sevan, Kahn, Maria, Gornsawun, Gornpan, Penpitchaporn, Pimsupah, Chu, Cindy S., Nosten, François, and Domingo, Gonzalo J.
- Published
- 2019
- Full Text
- View/download PDF
33. Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood.
- Author
-
Bancone, Germana, Gornsawun, Gornpan, Chu, Cindy S., Porn, Pen, Pal, Sampa, Bansil, Pooja, Domingo, Gonzalo J., and Nosten, Francois
- Subjects
GLUCOSE 6-phosphatase ,DEHYDROGENASES ,HEMOLYSIS & hemolysins ,HYPERBILIRUBINEMIA ,BRAIN damage ,VENOUS pressure - Abstract
Introduction: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzymopathy in the human population affecting an estimated 8% of the world population, especially those living in areas of past and present malaria endemicity. Decreased G6PD enzymatic activity is associated with drug-induced hemolysis and increased risk of severe neonatal hyperbilirubinemia leading to brain damage. The G6PD gene is on the X chromosome therefore mutations cause enzymatic deficiency in hemizygote males and homozygote females while the majority of heterozygous females have an intermediate activity (between 30–80% of normal) with a large distribution into the range of deficiency and normality. Current G6PD qualitative tests are unable to diagnose G6PD intermediate activities which could hinder wide use of 8-aminoquinolines for Plasmodium vivax elimination. The aim of the study was to assess the diagnostic performances of the new Carestart G6PD quantitative biosensor. Methods: A total of 150 samples of venous blood with G6PD deficient, intermediate and normal phenotypes were collected among healthy volunteers living along the north-western Thailand-Myanmar border. Samples were analyzed by complete blood count, by gold standard spectrophotometric assay using Trinity kits and by the latest model of Carestart G6PD biosensor which analyzes both G6PD and hemoglobin. Results: Bland-Altman comparison of the CareStart normalized G6PD values to that of the gold standard assay showed a strong bias in values resulting in poor area under-the-curve values for both 30% and 80% thresholds. Performing a receiver operator curve identified threshold values for the CareStart product equivalent to the 30% and 80% gold standard values with good sensitivity and specificity values, 100% and 92% (for 30% G6PD activity) and 92% and 94% (for 80% activity) respectively. Conclusion: The Carestart G6PD biosensor represents a significant improvement for quantitative diagnosis of G6PD deficiency over previous versions. Further improvements and validation studies are required to assess its utility for informing radical cure decisions in malaria endemic settings. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
34. Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria.
- Author
-
Watson, James, Taylor, Walter R. J., Bancone, Germana, Chu, Cindy S., Jittamala, Podjanee, and White, Nicholas J.
- Subjects
ANTIMALARIALS ,GLUCOSE-6-phosphate dehydrogenase ,ALLELES ,MALARIA prevention ,PREVENTIVE medicine - Abstract
Background: The 8-aminoquinoline antimalarials, the only drugs which prevent relapse of vivax and ovale malaria (radical cure), cause dose-dependent oxidant haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients with <30% and <70% of normal G6PD activity are not given standard regimens of primaquine and tafenoquine, respectively. Both drugs are currently considered contraindicated in pregnant and lactating women. Methods: Quantitative G6PD enzyme activity data from 5198 individuals were used to estimate the proportions of heterozygous females who would be ineligible for treatment at the 30% and 70% activity thresholds, and the relationship with the severity of the deficiency. This was used to construct a simple model relating allele frequency in males to the potential population coverage of tafenoquine and primaquine under current prescribing restrictions. Findings: Independent of G6PD deficiency, the current pregnancy and lactation restrictions will exclude ~13% of females from radical cure treatment. This could be reduced to ~4% if 8-aminoquinolines can be prescribed to women breast-feeding infants older than 1 month. At a 30% activity threshold, approximately 8–19% of G6PD heterozygous women are ineligible for primaquine treatment; at a 70% threshold, 50–70% of heterozygous women and approximately 5% of G6PD wild type individuals are ineligible for tafenoquine treatment. Thus, overall in areas where the G6PDd allele frequency is >10% more than 15% of men and more than 25% of women would be unable to receive tafenoquine. In vivax malaria infected patients these proportions will be lowered by any protective effect against P. vivax conferred by G6PD deficiency. Conclusion: If tafenoquine is deployed for radical cure, primaquine will still be needed to obtain high population coverage. Better radical cure antimalarial regimens are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
35. Singapore's Anopheles sinensis Form A is susceptible to Plasmodium vivax isolates from the western Thailand-Myanmar border.
- Author
-
Pang, Sook-Cheng, Andolina, Chiara, Malleret, Benoit, Christensen, Peter R., Lam-Phua, Sai-Gek, Bin Abdul Razak, Muhammad Aliff, Chee-Seng Chong, Daiqin Li, Chu, Cindy S., Russell, Bruce, Rénia, Laurent, Lee-Ching Ng, and Nosten, Francois
- Subjects
ANOPHELES ,PLASMODIUM vivax ,MALARIA ,KARYOTYPES - Abstract
Background: Singapore has been certified malaria-free by the World Health Organization since November 1982. However, sporadic autochthonous malaria outbreaks do occur. In one of the most recent outbreaks of vivax malaria, an entomological investigation identified Anopheles sinensis as the most probable vector. As metaphase karyotype studies divided An. sinensis into two forms, A and B, with different vector competence: the investigation of vector competence of An. sinensis found in Singapore was thus pursued using Plasmodium vivax field isolates from the Thailand-Myanmar border. Methods: Adults and larvae An. sinensis were collected from Singapore from 14 different locations, using various trapping and collection methods between September 2013 and January 2016. Molecular identification of An. sinensis species were conducted by amplifying the ITS2 and CO1 region using PCR. Experimental infections of An. sinensis using blood from seven patients infected with P. vivax from the Thailand-Myanmar border were conducted with Anopheles cracens (An. dirus B) as control. Results: Phylogenetic analysis showed that An. sinensis ( F
22 , F2 and collected from outbreak areas) found in Singapore was entirely Form A, and closely related to An. sinensis Form A from Thailand. Artificial infection of these Singapore strain An. sinensis Form A resulted in the development of oocysts in four experiments, with the number of sporozoites produced by one An. sinensis ranging from 4301 to 14,538. Conclusions: Infection experiments showed that An. sinensis Form A from Singapore was susceptible to Thai-Myanmar P. vivax strain, suggesting a potential role as a malaria vector in Singapore. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
36. Using G6PD tests to enable the safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: A cost-effectiveness analysis.
- Author
-
Devine, Angela, Lubell, Yoel, Chu, Cindy S., Bancone, Germana, Nosten, François, Price, Ric N., Parmiter, Minnie, and Yeung, Shunmay
- Subjects
PLASMODIUM vivax ,GLUCOSE-6-phosphatase ,HEMOLYSIS & hemolysins ,PRIMAQUINE ,DIAGNOSIS ,THERAPEUTICS - Abstract
Background: Primaquine is the only licensed antimalarial for the radical cure of Plasmodium vivax infections. Many countries, however, do not administer primaquine due to fear of hemolysis in those with glucose-6-phosphate dehydrogenase (G6PD) deficiency. In other settings, primaquine is given without G6PD testing, putting patients at risk of hemolysis. New rapid diagnostic tests (RDTs) offer the opportunity to screen for G6PD deficiency prior to treatment with primaquine. Here we assessed the cost-effectiveness of using G6PD RDTs on the Thailand-Myanmar border and provide the model as an online tool for use in other settings. Methods/Principal findings: Decision tree models for the management of P. vivax malaria evaluated the costs and disability-adjusted life-years (DALYs) associated with recurrences and primaquine-induced hemolysis from a health care provider perspective. Screening with G6PD RDTs before primaquine use was compared to (1) giving chloroquine alone and (2) giving primaquine without screening. Data were taken from a recent study on the impact of primaquine on P. vivax recurrences and a literature review. Compared to the use of chloroquine alone, the screening strategy had similar costs while averting 0.026 and 0.024 DALYs per primary infection in males and females respectively. Compared to primaquine administered without screening, the screening strategy provided modest cost savings while averting 0.011 and 0.004 DALYs in males and females respectively. The probabilistic sensitivity analyses resulted in a greater than 75% certainty that the screening strategy was cost-effective at a willingness to pay threshold of US$500, which is well below the common benchmark of per capita gross domestic product for Myanmar. Conclusions/Significance: In this setting G6PD RDTs could avert DALYs by reducing recurrences and reducing hemolytic risk in G6PD deficient patients at low costs or cost savings. The model results are limited by the paucity of data available in the literature for some parameter values, including the mortality rates for both primaquine-induced hemolysis and P. vivax. The online model provides an opportunity to use different parameter estimates to examine the validity of these findings in other settings. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
37. Management of relapsing Plasmodium vivax malaria.
- Author
-
Chu, Cindy S and White, Nicholas J
- Abstract
Introduction: Relapses are important contributors to illness and morbidity in Plasmodium vivax and P. ovale infections. Relapse prevention (radical cure) with primaquine is required for optimal management, control and ultimately elimination of Plasmodium vivax malaria. A review was conducted with publications in English, French, Portuguese and Spanish using the search terms 'P. vivax' and 'relapse'.Areas Covered: Hypnozoites causing relapses may be activated weeks or months after initial infection. Incidence and temporal patterns of relapse varies geographically. Relapses derive from parasites either genetically similar or different from the primary infection indicating that some derive from previous infections. Malaria illness itself may activate relapse. Primaquine is the only widely available treatment for radical cure. However, it is often not given because of uncertainty over the risks of primaquine induced haemolysis when G6PD deficiency testing is unavailable. Recommended dosing of primaquine for radical cure in East Asia and Oceania is 0.5 mg base/kg/day and elsewhere is 0.25 mg base/kg/day. Alternative treatments are under investigation. Expert commentary: Geographic heterogeneity in relapse patterns and chloroquine susceptibility of P. vivax, and G6PD deficiency epidemiology mean that radical treatment should be given much more than it is today. G6PD testing should be made widely available so primaquine can be given more safely. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
38. The suitability of laboratory-bred Anopheles cracens for the production of Plasmodium vivax sporozoites.
- Author
-
Andolina, Chiara, Landier, Jordi, Carrara, Verena, Chu, Cindy S., Franetich, Jean-Francois, Roth, Alison, Rénia, Laurent, Roucher, Clémentine, White, Nick J., Snounou, Georges, and Nosten, François
- Subjects
ANOPHELES ,MOSQUITOES ,SPOROZOITES ,PLASMODIUM vivax ,INFECTIOUS disease transmission - Abstract
Background: A stenogamous colony of Anopheles cracens (A. dirus B) established 20 years ago in a Thai insectary proved susceptible to Plasmodium vivax. However, routine sporozoite production by feeding on field-collected blood samples has not been described. The setting-up of an A. cracens colony in an insectary on the Thai-Myanmar border and the process of using P. vivax field samples for the production of infectious sporozoites are described. Methods: The colony was started in 2012 from egg batches that were sent from the Department of Parasitology, Faculty of Medicine, University of Chiang Mai, to the Shoklo Malaria Research Unit (SMRU), on wet filter paper in sealed Petri dishes. From May 2013 to December 2014, P. vivax-infected blood samples collected from patients seeking care at SMRU clinics were used for membrane feeding assays and sporozoite production. Results: Mosquitoes were fed on blood samples from 55 patients, and for 38 (69 %) this led to the production sporozoites. The average number of sporozoites obtained per mosquito was 26,112 (range 328-79,310). Gametocytaemia was not correlated with mosquito infectiousness (p = 0.82), or with the number of the sporozoites produced (Spearman's ρ = -0.016, p = 0.905). Infectiousness did not vary with the date of collection or the age of the patient. Mosquito survival was not correlated with sporozoite load (Spearman's ρ = 0.179, p = 0.282). Conclusion: Consistent and routine P. vivax sporozoites production confirms that A. cracens is highly susceptible to P. vivax infection. Laboratory-bred colonies of this vector are suitable for experimental transmission protocols and thus constitute a valuable resource. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
39. Suitability of Capillary Blood for Quantitative Assessment of G6PD Activity and Performances of G6PD Point-of-Care Tests.
- Author
-
Bancone, Germana, Chu, Cindy S., Nongnud Chowwiwat, Somsakchaicharoen, Raweewan, Wilaisrisak, Pornpimon, Charunwatthana, Prakaykaew, Bansil, Pooja, McGray, Sarah, Domingo, Gonzalo J., and Nosten, Francois H.
- Published
- 2015
- Full Text
- View/download PDF
40. Methylene blue inhibits the asexual development of vivax malaria parasites from a region of increasing chloroquine resistance.
- Author
-
Suwanarusk, Rossarin, Russell, Bruce, Ong, Alice, Sriprawat, Kanlaya, Chu, Cindy S, PyaePhyo, Aung, Malleret, Benoit, Nosten, François, and Renia, Laurent
- Subjects
ANTIMALARIALS ,CELL physiology ,CHLOROQUINE ,DRUG resistance ,FLOW cytometry ,MALARIA ,METHYLENE blue ,MICROBIOLOGICAL techniques ,PARASITOLOGY ,PROTOZOA ,RESEARCH funding ,PHARMACODYNAMICS - Abstract
Objectives: Methylene blue, once discarded due to its unsettling yet mild side effects, has now found a renewed place in the pharmacopoeia of modern medicine. The continued spread of drug-resistant Plasmodium vivax and Plasmodium falciparum has also led to a recent re-examination of methylene blue's potent antimalarial properties. Here we examine the ex vivo susceptibility profile of Plasmodium spp. isolates to methylene blue; the isolates were from a region on the Thai-Myanmar border where there are increasing rates of failure when treating vivax malaria with chloroquine.Methods: To do this we used a newly developed ex vivo susceptibility assay utilizing flow cytometry and a portable flow cytometer with a near-UV laser.Results: P. vivax (median methylene blue IC50 3.1 nM, IQR 1.7-4.3 nM) and P. falciparum (median methylene blue IC50 1.8 nM, IQR 1.6-2.3 nM) are susceptible to methylene blue treatment at physiologically relevant levels. Unfortunately, the addition of chloroquine to combination treatments with methylene blue significantly reduces the ex vivo effectiveness of this molecule.Conclusions: Our data support further efforts to employ methylene blue as a safe, low-cost antimalarial to treat drug-resistant malaria. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
41. Characterization of G6PD Genotypes and Phenotypes on the Northwestern Thailand-Myanmar Border.
- Author
-
Bancone, Germana, Chu, Cindy S., Somsakchaicharoen, Raweewan, Chowwiwat, Nongnud, Parker, Daniel M., Charunwatthana, Prakaykaew, White, Nicholas J., and Nosten, François H.
- Subjects
- *
MALARIA treatment , *PLASMODIUM vivax , *ANTIMALARIALS , *GLUCOSE-6-phosphate dehydrogenase , *GENETIC mutation , *DISEASE susceptibility - Abstract
Mutations in the glucose-6-phosphate dehydrogenase (G6PD) gene result in red blood cells with increased susceptibility to oxidative damage. Significant haemolysis can be caused by primaquine and other 8-aminoquinoline antimalarials used for the radical treatment of Plasmodium vivax malaria. The distribution and phenotypes of mutations causing G6PD deficiency in the male population of migrants and refugees in a malaria endemic region on the Thailand-Myanmar border were characterized. Blood samples for G6PD fluorescent spot test (FST), G6PD genotyping, and malaria testing were taken from 504 unrelated males of Karen and Burman ethnicities presenting to the outpatient clinics. The overall frequency of G6PD deficiency by the FST was 13.7%. Among the deficient subjects, almost 90% had the Mahidol variant (487G>A) genotype. The remaining subjects had Chinese-4 (392G>T), Viangchan (871G>A), Açores (595A>G), Seattle (844G>C) and Mediterranean (563C>T) variants. Quantification of G6PD activity was performed using a modification of the standard spectrophotometric assay on a subset of 24 samples with Mahidol, Viangchan, Seattle and Chinese-4 mutations; all samples showed a residual enzymatic activity below 10% of normal and were diagnosed correctly by the FST. Further studies are needed to characterise the haemolytic risk of using 8-aminoquinolines in patients with these genotypes. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
42. Uncomplicated Plasmodium vivax malaria in pregnancy associated with mortality from acute respiratory distress syndrome.
- Author
-
McGready, Rose, Wongsaen, Klanarong, Chu, Cindy S., Nay Win Tun, Chotivanich, Kesinee, White, Nicholas J., and Nosten, François
- Subjects
PLASMODIUM vivax ,MALARIA in pregnancy ,ADULT respiratory distress syndrome treatment ,MEDICAL screening ,PREGNANT women ,MEFLOQUINE ,POLYMERASE chain reaction - Abstract
The association between severe malaria and Plasmodium vivax species is contentious. On the Thai-Myanmar border, all pregnant women are followed systematically with active weekly malaria screening. Over a 27-year period of providing antenatal care, 48,983 have been prospectively followed until pregnancy outcome (miscarriage or delivery) and 4,298 women have had P. vivax detected at least once. Reported here is the first known P. vivax-associated death amongst these women. The initial patient presentation was of uncomplicated P. vivax (0.5% parasitaemia) in a term, multigravida woman who responded rapidly to oral artesunate and mefloquine treatment, clearing her blood stage parasites within 48 hours. The patient appeared well, was ambulatory and due to be discharged but became unwell with acute respiratory distress syndrome (ARDS) requiring ventilation three days (67 hours) into treatment. Despite induction and delivery of a stillborn foetus, ventilatory requirements increased and the patient died on day 7. The patient had a low body mass index. Sensitive detection with nested PCR confirmed only the presence of P. vivax species and concomitant infections such as tuberculosis and human immunodeficiency virus (HIV) were also ruled out. The contemporaneous treatment of acute uncomplicated P. vivax and the onset of ARDS on day 3 in this patient implies a possible but unconfirmed association with death in this patient. Assuming this death was caused by P. vivax, the risk of ARDS-related maternal mortality in this setting did not differ significantly between Plasmodium falciparum and P. vivax (0.24 per 1,000 (1/4,158) versus 0.23 per 1,000 (1/4,298), contrary to the increased risk of maternal mortality from P. falciparum compared to P. vivax, 2.89 per 1,000 (12/4,158) versus 0.23 per 1,000 (1/4,298), P = 0.003. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
43. Effect of Early Detection and Treatment on Malaria Related Maternal Mortality on the North-Western Border of Thailand 1986-2010.
- Author
-
McGready, Rose, Boel, Machteld, Rijken, Marcus J., Ashley, Elizabeth A., Thein Cho, Oh Moo, Moo Koh Paw, Pimanpanarak, Mupawjay, Hkirijareon, Lily, Carrara, Verena I., Khin Maung Lwin, Aung Pyae Phyo, Turner, Claudia, Chu, Cindy S., van Vugt, Michele, Price, Richard N., Luxemburger, Christine, ter Kuile, Feiko O., Saw Oo Tan, and Proux, Stephane
- Subjects
MALARIA treatment ,MATERNAL mortality ,SEPSIS ,BLOOD diseases ,COMMUNICABLE diseases - Abstract
Introduction: Maternal mortality is high in developing countries, but there are few data in high-risk groups such as migrants and refugees in malaria-endemic areas. Trends in maternal mortality were followed over 25 years in antenatal clinics prospectively established in an area with low seasonal transmission on the north-western border of Thailand. Methods and Findings: All medical records from women who attended the Shoklo Malaria Research Unit antenatal clinics from 12th May 1986 to 31st December 2010 were reviewed, and maternal death records were analyzed for causality. There were 71 pregnancy-related deaths recorded amongst 50,981 women who attended antenatal care at least once. Three were suicide and excluded from the analysis as incidental deaths. The estimated maternal mortality ratio (MMR) overall was 184 (95%CI 150-230) per 100,000 live births. In camps for displaced persons there has been a six-fold decline in the MMR from 499 (95%CI 200-780) in 1986-90 to 79 (40-170) in 2006-10, p<0.05. In migrants from adjacent Myanmar the decline in MMR was less significant: 588 (100-3260) to 252 (150-430) from 1996-2000 to 2006-2010. Mortality from P.falciparum malaria in pregnancy dropped sharply with the introduction of systematic screening and treatment and continued to decline with the reduction in the incidence of malaria in the communities. P.vivax was not a cause of maternal death in this population. Infection (non-puerperal sepsis and P.falciparum malaria) accounted for 39.7 (27/68) % of all deaths. Conclusions: Frequent antenatal clinic screening allows early detection and treatment of falciparum malaria and substantially reduces maternal mortality from P.falciparum malaria. No significant decline has been observed in deaths from sepsis or other causes in refugee and migrant women on the Thai-Myanmar border. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
44. Single-genome sequencing reveals within-host evolution of human malaria parasites.
- Author
-
Dia, Aliou, Jett, Catherine, Trevino, Simon G., Chu, Cindy S., Sriprawat, Kanlaya, Anderson, Timothy J.C., Nosten, François, and Cheeseman, Ian H.
- Abstract
Population genomics of bulk malaria infections is unable to examine intrahost evolution; therefore, most work has focused on the role of recombination in generating genetic variation. We used single-cell sequencing protocol for low-parasitaemia infections to generate 406 near-complete single Plasmodium vivax genomes from 11 patients sampled during sequential febrile episodes. Parasite genomes contain hundreds of de novo mutations, showing strong signatures of selection, which are enriched in the ApiAP2 family of transcription factors, known targets of adaptation. Comparing 315 P. falciparum single-cell genomes from 15 patients with our P. vivax data, we find broad complementary patterns of de novo mutation at the gene and pathway level, revealing the importance of within-host evolution during malaria infections. [Display omitted] • Single-cell sequencing protocol suited for low-parasitaemia malaria infections • Single genomes from recurrent P. vivax infections capture intrahost relatedness • Putative de novo mutations identify recurrent mutations in the ApiAP2 gene family • Reanalysis of P. falciparum single-cell data identifies convergent signals of mutation Dia et al. develop a single-cell sequencing protocol to capture the genetic diversity of low-parasitaemia malaria infections. Application of this approach to recurrent Plasmodium vivax infection captures intrahost relatedness and signatures of selection. Comparison with published P. falciparum data identifies gene homologs recurrently mutated in both species. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
45. Plasmodium vivax Malaria.
- Author
-
Beeson, James G., Chu, Cindy S., Richards, Jack S., Nosten, Francois, and Fowkes, Freya J. I.
- Published
- 2015
- Full Text
- View/download PDF
46. G6PD Variants and Haemolytic Sensitivity to Primaquine and Other Drugs.
- Author
-
Bancone, Germana and Chu, Cindy S.
- Subjects
PRIMAQUINE ,GLUCOSE-6-phosphate dehydrogenase deficiency ,TREATMENT effectiveness ,FAVA bean ,ENZYME deficiency ,MALARIA - Abstract
Restrictions on the cultivation and ingestion of fava beans were first reported as early as the fifth century BC. Not until the late 19th century were clinical descriptions of fava-induced disease reported and soon after characterised as "favism" in the early 20th century. It is now well known that favism as well as drug-induced haemolysis is caused by a deficiency of the glucose-6-phosphate dehydrogenase (G6PD) enzyme, one of the most common enzyme deficiency in humans. Interest about the interaction between G6PD deficiency and therapeutics has increased recently because mass treatment with oxidative 8-aminoquinolines is necessary for malaria elimination. Historically, assessments of haemolytic risk have focused on the clinical outcomes (e.g., haemolysis) associated with either a simplified phenotypic G6PD characterisation (deficient or normal) or an ill-fitting classification of G6PD genetic variants. It is increasingly apparent that detailed knowledge of both aspects is required for a complete understanding of haemolytic risk. While more attention has been devoted recently to better phenotypic characterisation of G6PD activity (including the development of new point-of care tests), the classification of G6PD variants should be revised to be clinically useful in malaria eliminating countries and in populations with prevalent G6PD deficiency. The scope of this work is to summarize available literature on drug-induced haemolysis among individuals with different G6PD variants and to highlight knowledge gaps that could be filled with further clinical and laboratory research. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
47. Tafenoquine and G6PD: a primer for clinicians.
- Author
-
Chu, Cindy S and Freedman, David O
- Subjects
- *
GLUCOSE-6-phosphate dehydrogenase deficiency , *GLUCOSE-6-phosphate dehydrogenase , *THERAPEUTICS , *PLASMODIUM vivax , *INFORMATION resources management - Abstract
Background: Tafenoquine, an 8-aminoquinoline, is now indicated for causal prophylaxis against all human malarias and as radical curative (anti-relapse) treatment against Plasmodium vivax and Plasmodium ovale. As with other 8-aminoquinolines, tafenoquine causes hemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency (hemizygous males and homozygous females) and is contraindicated in this population. Those with intermediate G6PD activity (heterozygous females) are also at risk for hemolysis. Awareness of how to prescribe tafenoquine in relation to G6PD status is needed so it can be used safely.Methods: A standard literature search was performed on varying combinations of the terms tafenoquine, Arakoda, Kodatef, Krintafel, Kozenis, primaquine, G6PD deficiency, malaria prophylaxis and radical cure. The data were gathered and interpreted to review how tafenoquine should be prescribed in consideration of the G6PD status of an individual and traveller.Results: Tafenoquine should only be given to those with G6PD activity >70% of the local population median. Qualitative G6PD tests are sufficient for diagnosing G6PD deficiency in males. However, in females quantitative G6PD testing is necessary to differentiate deficient, intermediate and normal G6PD statuses. Testing for G6PD deficiency is mandatory before tafenoquine prescription. Measures can be taken to avoid tafenoquine administration to ineligible individuals (i.e. due to G6PD status, age, pregnancy and lactation). Primaquine is still necessary for some of these cases. This review provides actions that can be taken to diagnose and manage hemolysis when tafenoquine is given inadvertently to ineligible individuals.Conclusion: Attention to G6PD status is required for safe prescription of tafenoquine. A high index of suspicion is needed if hemolysis occurs. Clinicians should seek evidence-based information for the management and treatment of iatrogenicy hemolysis caused by 8-aminoquinolines. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
48. Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis.
- Author
-
Commons, Robert J, Rajasekhar, Megha, Edler, Peta, Abreha, Tesfay, Awab, Ghulam R, Baird, J Kevin, Barber, Bridget E, Chu, Cindy S, Cui, Liwang, Daher, André, Gonzalez-Ceron, Lilia, Grigg, Matthew J, Hwang, Jimee, Karunajeewa, Harin, Lacerda, Marcus V G, Ladeia-Andrade, Simone, Lidia, Kartini, Llanos-Cuentas, Alejandro, Longley, Rhea J, and Pereira, Dhelio B
- Subjects
- *
PLASMODIUM vivax , *PRIMAQUINE , *DISEASE relapse , *POISSON regression , *MEDICAL research - Abstract
Primaquine is used to eliminate Plasmodium vivax hypnozoites, but its optimal dosing regimen remains unclear. We undertook a systematic review and individual patient data meta-analysis to investigate the efficacy and tolerability of different primaquine dosing regimens to prevent P vivax recurrence. For this systematic review and individual patient data meta-analysis, we searched MEDLINE, Web of Science, Embase, and Cochrane Central for prospective clinical studies of uncomplicated P vivax from endemic countries published between Jan 1, 2000, and June 8, 2023. We included studies if they had active follow-up of at least 28 days, and if they included a treatment group with daily primaquine given over multiple days, where primaquine was commenced within 7 days of schizontocidal treatment and was given alone or coadministered with chloroquine or one of four artemisinin-based combination therapies (ie, artemether–lumefantrine, artesunate–mefloquine, artesunate–amodiaquine, or dihydroartemisinin–piperaquine). We excluded studies if they were on prevention, prophylaxis, or patients with severe malaria, or if data were extracted retrospectively from medical records outside of a planned trial. For the meta-analysis, we contacted the investigators of eligible trials to request individual patient data and we then pooled data that were made available by Aug 23, 2021. We assessed the effects of total dose and duration of primaquine regimens on the rate of first P vivax recurrence between day 7 and day 180 by Cox's proportional hazards regression (efficacy analysis). The effect of primaquine daily dose on gastrointestinal symptoms on days 5–7 was assessed by modified Poisson regression (tolerability analysis). The study was registered with PROSPERO, CRD42019154470. Of 226 identified studies, 23 studies with patient-level data from 6879 patients from 16 countries were included in the efficacy analysis. At day 180, the risk of recurrence was 51·0% (95% CI 48·2–53·9) in 1470 patients treated without primaquine, 19·3% (16·9–21·9) in 2569 patients treated with a low total dose of primaquine (approximately 3·5 mg/kg), and 8·1% (7·0–9·4) in 2811 patients treated with a high total dose of primaquine (approximately 7 mg/kg), regardless of primaquine treatment duration. Compared with treatment without primaquine, the rate of P vivax recurrence was lower after treatment with low-dose primaquine (adjusted hazard ratio 0·21, 95% CI 0·17–0·27; p<0·0001) and high-dose primaquine (0·10, 0·08–0·12; p<0·0001). High-dose primaquine had greater efficacy than low-dose primaquine in regions with high and low relapse periodicity (ie, the time from initial infection to vivax relapse). 16 studies with patient-level data from 5609 patients from ten countries were included in the tolerability analysis. Gastrointestinal symptoms on days 5–7 were reported by 4·0% (95% CI 0·0–8·7) of 893 patients treated without primaquine, 6·2% (0·5–12·0) of 737 patients treated with a low daily dose of primaquine (approximately 0·25 mg/kg per day), 5·9% (1·8–10·1) of 1123 patients treated with an intermediate daily dose (approximately 0·5 mg/kg per day) and 10·9% (5·7–16·1) of 1178 patients treated with a high daily dose (approximately 1 mg/kg per day). 20 of 23 studies included in the efficacy analysis and 15 of 16 in the tolerability analysis had a low or unclear risk of bias. Increasing the total dose of primaquine from 3·5 mg/kg to 7 mg/kg can reduce P vivax recurrences by more than 50% in most endemic regions, with a small associated increase in gastrointestinal symptoms. Australian National Health and Medical Research Council, Bill & Melinda Gates Foundation, and Medicines for Malaria Venture. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis.
- Author
-
Rajasekhar, Megha, Simpson, Julie A, Ley, Benedikt, Edler, Peta, Chu, Cindy S, Abreha, Tesfay, Awab, Ghulam R, Baird, J Kevin, Bancone, Germana, Barber, Bridget E, Grigg, Matthew J, Hwang, Jimee, Karunajeewa, Harin, Lacerda, Marcus V G, Ladeia-Andrade, Simone, Llanos-Cuentas, Alejandro, Pukrittayakamee, Sasithon, Rijal, Komal R, Saravu, Kavitha, and Sutanto, Inge
- Subjects
- *
PLASMODIUM vivax , *PRIMAQUINE , *GLUCOSE-6-phosphate dehydrogenase , *MALARIA , *MEDICAL records - Abstract
Primaquine radical cure is used to treat dormant liver-stage parasites and prevent relapsing Plasmodium vivax malaria but is limited by concerns of haemolysis. We undertook a systematic review and individual patient data meta-analysis to investigate the haematological safety of different primaquine regimens for P vivax radical cure. For this systematic review and individual patient data meta-analysis, we searched MEDLINE, Web of Science, Embase, and Cochrane Central for prospective clinical studies of uncomplicated P vivax from endemic countries published between Jan 1, 2000, and June 8, 2023. We included studies if they had active follow-up of at least 28 days, if they included a treatment group with daily primaquine given over multiple days where primaquine was commenced within 3 days of schizontocidal treatment and was given alone or coadministered with chloroquine or one of four artemisinin-based combination therapies (ie, artemether–lumefantrine, artesunate–mefloquine, artesunate–amodiaquine, or dihydroartemisinin–piperaquine), and if they recorded haemoglobin or haematocrit concentrations on day 0. We excluded studies if they were on prevention, prophylaxis, or patients with severe malaria, or if data were extracted retrospectively from medical records outside of a planned trial. For the meta-analysis, we contacted the investigators of eligible trials to request individual patient data and we then pooled data that were made available by Aug 23, 2021. The main outcome was haemoglobin reduction of more than 25% to a concentration of less than 7 g/dL by day 14. Haemoglobin concentration changes between day 0 and days 2–3 and between day 0 and days 5–7 were assessed by mixed-effects linear regression for patients with glucose-6-phosphate dehydrogenase (G6PD) activity of (1) 30% or higher and (2) between 30% and less than 70%. The study was registered with PROSPERO, CRD42019154470 and CRD42022303680. Of 226 identified studies, 18 studies with patient-level data from 5462 patients from 15 countries were included in the analysis. A haemoglobin reduction of more than 25% to a concentration of less than 7 g/dL occurred in one (0·1%) of 1208 patients treated without primaquine, none of 893 patients treated with a low daily dose of primaquine (<0·375 mg/kg per day), five (0·3%) of 1464 patients treated with an intermediate daily dose (0·375 mg/kg per day to <0·75 mg/kg per day), and six (0·5%) of 1269 patients treated with a high daily dose (≥0·75 mg/kg per day). The covariate-adjusted mean estimated haemoglobin changes at days 2–3 were –0·6 g/dL (95% CI –0·7 to –0·5), –0·7 g/dL (–0·8 to –0·5), –0·6 g/dL (–0·7 to –0·4), and –0·5 g/dL (–0·7 to –0·4), respectively. In 51 patients with G6PD activity between 30% and less than 70%, the adjusted mean haemoglobin concentration on days 2–3 decreased as G6PD activity decreased; two patients in this group who were treated with a high daily dose of primaquine had a reduction of more than 25% to a concentration of less than 7 g/dL. 17 of 18 included studies had a low or unclear risk of bias. Treatment of patients with G6PD activity of 30% or higher with 0·25–0·5 mg/kg per day primaquine regimens and patients with G6PD activity of 70% or higher with 0·25–1 mg/kg per day regimens were associated with similar risks of haemolysis to those in patients treated without primaquine, supporting the safe use of primaquine radical cure at these doses. Australian National Health and Medical Research Council, Bill & Melinda Gates Foundation, and Medicines for Malaria Venture. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Primaquine-induced haemolysis in females heterozygous for G6PD deficiency.
- Author
-
Chu, Cindy S., Bancone, Germana, Nosten, François, White, Nicholas J., and Luzzatto, Lucio
- Subjects
- *
HEMOLYTIC anemia , *HEMOLYTIC anemia diagnosis , *ENZYME deficiency , *PRIMAQUINE , *DAPSONE , *PATIENTS - Abstract
Oxidative agents can cause acute haemolytic anaemia in persons with G6PD deficiency. Understanding the relationship between G6PD genotype and the phenotypic expression of the enzyme deficiency is necessary so that severe haemolysis can be avoided. The patterns of oxidative haemolysis have been well described in G6PD deficient hemizygous males and homozygous females; and haemolysis in the proportionally more numerous heterozygous females has been documented mainly following consumption of fava beans and more recently dapsone. It has long been known that 8-aminoquinolines, notably primaquine and tafenoquine, cause acute haemolysis in G6PD deficiency. To support wider use of primaquine in
Plasmodium vivax elimination, more data are needed on the haemolytic consequences of 8-aminoquinolines in G6PD heterozygous females. Two recent studies (in 2017) have provided precisely such data; and the need has emerged for the development of point of care quantitative testing of G6PD activity. Another priority is exploring alternative 8-aminoquinoline dosing regimens that are practical and improve safety in G6PD deficient individuals. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.